Synthesis, ADMET predictions, molecular docking studies, and in-vitro anticancer activity of some benzoxazines against A549 human lung cancer cells
Author:
Sulistyowaty Melanny Ika1, Widyowati Retno2ORCID, Putra Galih Satrio3, Budiati Tutuk4, Matsunami Katsuyoshi5
Affiliation:
1. Department of Pharmaceutical Chemistry , Faculty of Pharmacy, Universitas Airlangga , Surabaya , Indonesia 2. Department of Pharmacognosy and Phytochemistry , Faculty of Pharmacy, Universitas Airlangga , Surabaya , Indonesia 3. Department of Pharmaceutical Chemistry , Stikes Rumah Sakit Anwar Medika , Sidoarjo , Indonesia 4. Faculty of Pharmacy, Widya Mandala Catholic University , Surabaya , Indonesia 5. Department of Pharmacognosy , Graduate School of Biomedical and Health Sciences, Hiroshima University , Hiroshima , Japan
Abstract
Abstract
Objectives
This study aims to synthesize a series of benzoxazines (1–5) to be examined as an epidermal growth factor receptor (EGFR) inhibitor by in-silico study. The overexpression of EGFR causes the growth of normal lung cells to become uncontrollable, which may lead to cancer formation. We also conducted the absorption, distribution, metabolism, excretions and toxicity (ADMET) properties evaluation and also examined in vitro anticancer assay on human lung cancer cells line, which is A549.
Methods
Benzoxazines (1–5) were synthesized by reacting anthranilic acid and benzoyl chlorides. The structures of the compounds were determined with 1H, 13C-NMR, HRMS, UV and FT-IR spectrometric methods. Prediction of ADMET was using online pkCSM, and the molecular docking studies were using MVD with EGFR-TKIs as the target (PDB ID: 1M17). In vitro assay of anticancer activity was performed by MTT assay.
Results
Compounds 1–5 were successfully synthesized in good yields (71–84%). The ADMET prediction showed that benzoxazines are able to be absorbed through GIT, metabolized by CYP 450, and not hepatotoxic. The title compounds have a greater Moldock Score than Erlotinib, and 3 has the highest activity against A549 compared with other benzoxazines, IC50=36.6 μg/mL.
Conclusions
Compound (3) more active as anticancer against Human cancer cells line compared with other benzoxazines.
Publisher
Walter de Gruyter GmbH
Subject
Drug Discovery,Pharmacology,General Medicine,Physiology
Reference27 articles.
1. The Global Cancer Observatory. Indonesia fact sheet. Available from: https://gco.iarc.fr/today/data/factsheets/populations/360-indonesia-fact-sheets.pdf [Accessed 1 May 2019]. 2. Gillian, B, Drew, B, Neale, R, Zhaolin, X. Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update. J Thorac Dis 2010;2:48–51. 3. Sousa, AC, Silveira, C, Janeiro, A, Malveiro, S, Oliveira, AR, Felizardo, M, et al.. Detection of rare and novel EGFR mutations in NSCLC patients: implications for treatment-decision. Lung Canc 2020;139:35–40. 4. Grigoriu, B, Berghmans, T, Meert, AP. Management of EGFR mutated nonsmall cell lung carcinoma patients. Eur Respir J 2015;45:1132–41. 5. Kesuma, D, Putra, GS, Yuniarta, TA, Sulistyowaty, MI, Siswandono, BT. Synthesis of 2-phenyl-4H-benzo[d][1,3]oxazin-4-one and its biological activity against A549 cancer cell line through methionyl-tRNA synthetase inhibition approach on in-silico studies. Int J Pharmaceut Res 2019;11:1–11.
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Synthesis, spectroscopic elucidation, density functional theory calculation, and molecular docking studies of a novel series of tetradentate macrocyclic Schiff base ligands and their Zn(II) complexes and investigations of their antimicrobial, anti‐inflammatory, and anticancer activities;Applied Organometallic Chemistry;2023-12-12 2. QSAR study of benzylidene hydrazine benzamides derivatives with in vitro anticancer activity against human lung cancer cell line A459;Journal of Pharmacy & Pharmacognosy Research;2023-11-01 3. Synthesis, DFT calculation, molecular docking studies and biological evaluation of a novel series of Schiff base tetradentate macrocyclic ligands and their Zn(II) complexes as antimicrobial, anti-inflammatory and anticancer agents;Research on Chemical Intermediates;2023-08-08 4. Synthesis, In Silico Study, Antibacterial and Antifungal Activities of N-phenylbenzamides;International Journal of Molecular Sciences;2023-02-01 5. Benzoxazine: A Privileged Scaffold in Medicinal Chemistry;Current Medicinal Chemistry;2023-02
|
|